Biocon Raises Stake in Biocon Biologics to 94% via Share Swap and Cash Deal

Biocon Limited ( (IN:BIOCON) ) just unveiled an update.

Biocon Limited has increased its ownership in its unlisted material subsidiary, Biocon Biologics Limited (BBL), to around 94% of BBL’s fully diluted equity share capital by acquiring a total of 33.38 crore BBL shares. As part of this transaction, Biocon completed a share-swap deal on 5 January 2026, acquiring 26.19 crore BBL shares from Mylan Inc., Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP, and issued 17.13 crore new Biocon shares on a preferential basis to these investors at Rs 405.78 per share, resulting in the allottees collectively holding about 11.36% of Biocon’s expanded equity base. In addition, Biocon paid USD 200 million in cash to Mylan to acquire a further 7.18 crore BBL shares, with the remaining cash leg of the previously approved USD 400 million acquisition to follow. The transaction expands Biocon’s issued share capital and share count, implying equity dilution for existing shareholders but significantly consolidates Biocon’s control over BBL, reinforcing its strategic focus on the biologics segment and potentially enhancing operational and financial integration within the group.

More about Biocon Limited

Biocon Limited is an India-based biopharmaceutical company focused on biologics and related life sciences businesses, operating through its material subsidiary Biocon Biologics Limited (BBL). The group develops and markets biosimilars and specialty pharmaceuticals, positioning itself as a key player in the global biologics market with a strategy centered on scaling its biologics platform and consolidating ownership in its core subsidiary.

Average Trading Volume: 155,508

Technical Sentiment Signal: Strong Buy

Current Market Cap: 524.8B INR

Find detailed analytics on BIOCON stock on TipRanks’ Stock Analysis page.